<?xml version="1.0" encoding="UTF-8"?>

<Bundle xmlns="http://hl7.org/fhir">
  <id value="bundlepackageleaflet-es-94a96e39cfdcd8b378d12dd4063065f9"/>
  <meta>
    <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
  </meta>
  <language value="es"/>
  <identifier>
    <system value="https://www.gravitatehealth.eu/sid/doc"/>
    <value value="EU/1/18/1289/001"/>
  </identifier>
  <type value="document"/>
  <timestamp value="2023-06-27T10:09:22Z"/>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/Composition/composition-es-2a9c4333cfd126f2e7b73ad3cafd6949"/>
    <resource>
      <Composition>
        <id value="composition-es-2a9c4333cfd126f2e7b73ad3cafd6949"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
        </meta>
        <language value="es"/>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml" xml:lang="es" lang="es"><p><b>Generated Narrative: Composition</b><a name="composition-es-2a9c4333cfd126f2e7b73ad3cafd6949"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Composition &quot;composition-es-2a9c4333cfd126f2e7b73ad3cafd6949&quot;  (Language &quot;es&quot;) </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: id:Â c97bc0c62de4cf4143e63299ba73c5a3</p><p><b>status</b>: final</p><p><b>type</b>: Package Leaflet <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#100000155538)</span></p><p><b>category</b>: Raw <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="CodeSystem-epicategory-cs.html">Category of EPI</a>#R)</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="#Organization_mah-715f8a161ed438d0584510e5b4512caa">See above (Organization/mah-715f8a161ed438d0584510e5b4512caa)</a></p><p><b>title</b>: TEST PURPOSES ONLY - Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td>Official <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-composition-attestation-mode.html">Composition Attestation Mode</a>#official)</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
        </text>
        <identifier>
          <system value="https://spor.ema.europa.eu/rmswi/"/>
          <value value="c97bc0c62de4cf4143e63299ba73c5a3"/>
        </identifier>
        <status value="final"/>
        <type>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi/"/>
            <code value="100000155538"/>
          </coding>
          <text value="Package Leaflet"/>
        </type>
        <category>
          <coding>
            <system value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
            <code value="R"/>
            <display value="Raw"/>
          </coding>
        </category>
        <subject>
          <reference value="MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"/>
        </subject>
        <date value="2022-02-16T13:28:17Z"/>
        <author>
          <reference value="Organization/mah-715f8a161ed438d0584510e5b4512caa"/>
        </author>
        <title value="TEST PURPOSES ONLY - Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion"/>
        <attester>
          <mode>
            <coding>
              <system value="http://hl7.org/fhir/composition-attestation-mode"/>
              <code value="official"/>
            </coding>
          </mode>
          <time value="2022-02-16T13:28:17Z"/>
        </attester>
        <section>
          <title value="B. Package Leaflet"/>
          <code>
            <coding>
              <system value="https://spor.ema.europa.eu/rmswi/"/>
              <code value="100000155538"/>
            </coding>
            <text value="B. PACKAGE LEAFLET"/>
          </code>
          <text>
            <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
          </text>
          <emptyReason>
            <coding>
              <system value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
              <code value="unavailable"/>
            </coding>
          </emptyReason>
          <section>
            <title value="Package leaflet: Information for the user"/>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/rmswi/"/>
                <code value="100000155538"/>
              </coding>
              <text value="Package leaflet: Information for the user"/>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt 0pt 0pt 136pt; line-height:115%; font-size:11pt"><a name="page1" id="page1"></a><strong><span style="font-family:Times New Roman; font-size:11pt;">Prospecto: informaci&#243;n para el usuario</span></strong></p><p style="margin:0pt; line-height:12.65pt"><span style="font-family:Times New Roman; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 68pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Biktarvy 50 mg/200 mg/25 mg comprimidos recubiertos con pel&#237;cula</span></strong></p><p style="margin:0pt; line-height:0.05pt"><span style="font-family:Times New Roman; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">bictegravir/emtricitabina/tenofovir alafenamida</span></p><p style="margin:0pt; line-height:13.8pt"><span style="font-family:Times New Roman; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:12pt"><span style="font-family:Times New Roman; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 31.4pt 0pt 1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Lea todo el prospecto detenidamente antes de empezar a tomar este medicamento, porque contiene informaci&#243;n importante para usted.</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:12pt"><span style="font-family:Times New Roman; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 9.56pt; text-indent:0pt; text-align:justify; padding-left:19.44pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Conserve este prospecto, ya que puede tener que volver a leerlo.</span></li><li style="margin:0pt 0pt 0pt 9.56pt; text-indent:0pt; text-align:justify; padding-left:19.44pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si tiene alguna duda, consulte a su m&#233;dico o farmac&#233;utico.</span></li><li style="margin:0pt 30.4pt 0pt 9.56pt; text-indent:0pt; text-align:justify; padding-left:19.44pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Este medicamento se le ha recetado solamente a usted, y no debe d&#225;rselo a otras personas aunque tengan los mismos s&#237;ntomas que usted, ya que puede perjudicarles.</span></li><li style="margin:0pt 22.4pt 0pt 9.56pt; text-indent:0pt; text-align:justify; padding-left:19.44pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si experimenta efectos adversos, consulte a su m&#233;dico o farmac&#233;utico, incluso si se trata de efectos adversos que no aparecen en este prospecto. Ver secci&#243;n 4.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:12pt"><span style="font-family:Times New Roman; font-size:12pt">&#xa0;</span></p></div>
            </text>
          </section>
          <section>
            <title value="What is in this leaflet"/>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/rmswi/"/>
                <code value="100000155538"/>
              </coding>
              <text value="What is in this leaflet"/>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt 0pt 0pt 1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Contenido del prospecto</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:12pt"><span style="font-family:Times New Roman; font-size:12pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:15.1pt; font-family:Times New Roman; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Qu&#233; es Biktarvy y para qu&#233; se utiliza</span></li><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:15.1pt; font-family:Times New Roman; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Qu&#233; necesita saber antes de empezar a tomar Biktarvy</span></li><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:15.1pt; font-family:Times New Roman; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">C&#243;mo tomar Biktarvy</span></li><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:15.1pt; font-family:Times New Roman; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Posibles efectos adversos</span></li><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:15.1pt; font-family:Times New Roman; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Conservaci&#243;n de Biktarvy</span></li><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:15.1pt; font-family:Times New Roman; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Contenido del envase e informaci&#243;n adicional</span></li></ol><p style="margin:0pt; text-indent:-28.35pt; text-align:justify; line-height:115%; padding-left:28.35pt; font-size:12pt"><span style="font-family:Times New Roman; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p></div>
            </text>
          </section>
          <section>
            <title value="1. What 2 is and what it is used for"/>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/rmswi/"/>
                <code value="100000155538"/>
              </coding>
              <text value="1. What 2 is and what it is used for"/>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:12.8pt"><span style="font-family:Times New Roman; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Biktarvy contiene tres principios activos:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 5.4pt 0pt 9.75pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">bictegravir,</span></strong> <span style="font-family:Times New Roman; font-size:11pt">un medicamento antirretroviral conocido como inhibidor de la transferencia de las</span> <span style="font-family:Times New Roman; font-size:11pt">hebras de la integrasa (INI)</span></li><li style="margin:0pt 7.4pt 0pt 9.75pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">emtricitabina,</span></strong> <span style="font-family:Times New Roman; font-size:11pt">un medicamento antirretroviral de un tipo conocido como nucle&#243;sido inhibidor</span> <span style="font-family:Times New Roman; font-size:11pt">de la transcriptasa inversa (ITIAN)</span></li><li style="margin:0pt 12.4pt 0pt 9.75pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">tenofovir alafenamida,</span></strong> <span style="font-family:Times New Roman; font-size:11pt">un medicamento antirretroviral de un tipo conocido como nucle&#243;tido</span> <span style="font-family:Times New Roman; font-size:11pt">inhibidor de la transcriptasa inversa (ITIANt)</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:12pt"><span style="font-family:Times New Roman; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 75.4pt 0pt 1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Biktarvy es un comprimido &#250;nico para el tratamiento de la infecci&#243;n por el virus de la inmunodeficiencia humana 1 (VIH-1) en adultos.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:12pt"><span style="font-family:Times New Roman; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 17.4pt 0pt 0pt; text-indent:-1.35pt; text-align:justify; line-height:115%; padding-left:1.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Biktarvy reduce la cantidad de VIH presente en el organismo. Esto mejora el sistema inmunitario y disminuye el riesgo de desarrollar enfermedades asociadas con la infecci&#243;n por el VIH.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p></div>
            </text>
          </section>
          <section>
            <title value="2. What you need to know before you take 2"/>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/rmswi/"/>
                <code value="100000155538"/>
              </coding>
              <text value="2. What you need to know before you take 2"/>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:0.05pt"><span style="font-family:Times New Roman; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 14.4pt 0pt 0pt; line-height:117%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">No tome Biktarvy</span></strong></p><p style="margin:0pt 14.4pt 0pt 0pt; line-height:117%; font-size:11pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 14.4pt 0pt 9.8pt; text-indent:0pt; text-align:justify; padding-left:19.2pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si es al&#233;rgico a bictegravir, emtricitabina, tenofovir alafenamida</span></strong> <span style="font-family:Times New Roman; font-size:11pt">o a alguno de los dem&#225;s</span> <span style="font-family:Times New Roman; font-size:11pt">componentes de este medicamento (incluidos en la secci&#243;n 6 de este prospecto).</span></li></ul><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><a name="page2" id="page2"></a><strong><span style="font-family:Times New Roman; font-size:11pt;">Si actualmente est&#225; tomando alguno de los siguientes medicamentos:</span></strong></li><li style="list-style: none; display: inline"><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; text-align:justify; padding-left:20.09pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">rifampicina</span></strong> <span style="font-family:Times New Roman; font-size:11pt">utilizada para tratar algunas infecciones bacterianas como la tuberculosis</span></li><li style="margin:0pt 30.4pt 0pt 37.06pt; text-indent:0pt; text-align:justify; padding-left:20.04pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">hierba de San Juan</span></strong> <span style="font-family:Times New Roman; font-size:11pt">(</span><em><span style="font-family:Times New Roman; font-size:11pt;">Hypericum perforatum</span></em><span style="font-family:Times New Roman; font-size:11pt">, hip&#233;rico), un medicamento a base de</span> <span style="font-family:Times New Roman; font-size:11pt">plantas utilizado para la depresi&#243;n y la ansiedad, o productos que la contengan.</span></li></ul></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 36.4pt 0pt 15.77pt; text-indent:0pt; text-align:justify; padding-left:5.53pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si est&#225; tomando alguno de estos medicamentos,</span> <strong><span style="font-family:Times New Roman; font-size:11pt;">no tome Biktarvy y consulte a su m&#233;dico</span></strong> <strong><span style="font-family:Times New Roman; font-size:11pt;">inmediatamente.</span></strong></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Advertencias y precauciones</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Consulte a su m&#233;dico antes de empezar a tomar Biktarvy:</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 4.4pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si tiene problemas hep&#225;ticos o antecedentes de enfermedad hep&#225;tica, incluida la hepatitis.</span></strong> <span style="font-family:Times New Roman; font-size:11pt">Los pacientes que padecen de enfermedades hep&#225;ticas, como la hepatitis B o C cr&#243;nica, y est&#225;n en tratamiento con antirretrovirales tienen m&#225;s riesgo de presentar complicaciones hep&#225;ticas graves y potencialmente mortales. Si tiene infecci&#243;n por el virus de la hepatitis B, su m&#233;dico evaluar&#225; detenidamente la mejor pauta terap&#233;utica para usted.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 25.4pt 0pt 8.9pt; text-indent:0pt; text-align:justify; padding-left:19.2pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si tiene hepatitis B.</span></strong> <span style="font-family:Times New Roman; font-size:11pt">Los problemas hep&#225;ticos pueden empeorar despu&#233;s de dejar de tomar</span> <span style="font-family:Times New Roman; font-size:11pt">Biktarvy.</span></li></ul><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 18.4pt 0pt 15.77pt; text-indent:0pt; text-align:justify; padding-left:5.53pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No deje de tomar Biktarvy si tiene hepatitis B. Hable antes con su m&#233;dico. Puede consultar m&#225;s detalles en la secci&#243;n 3,</span> <em><span style="font-family:Times New Roman; font-size:11pt;">No interrumpa el tratamiento con Biktarvy.</span></em></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Mientras est&#233; tomando Biktarvy</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Una vez que empiece a tomar Biktarvy, est&#233; atento a:</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 27pt; text-indent:0pt; text-align:justify; padding-left:1.1pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Signos de inflamaci&#243;n o infecci&#243;n</span></strong></li><li style="margin:0pt 0pt 0pt 27pt; text-indent:0pt; text-align:justify; padding-left:1.1pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Dolor articular, rigidez o problemas &#243;seos</span></strong></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0.4pt 0pt 14.1pt; text-indent:0.1pt; text-align:justify; font-family:serif; font-size:11pt; list-style-position:inside"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si nota cualquiera de estos s&#237;ntomas, informe a su m&#233;dico inmediatamente.</span></strong> <span style="font-family:Times New Roman; font-size:11pt">Puede consultar</span> <span style="font-family:Times New Roman; font-size:11pt">m&#225;s informaci&#243;n en la secci&#243;n 4,</span> <em><span style="font-family:Times New Roman; font-size:11pt;">Posibles efectos adversos</span></em><span style="font-family:Times New Roman; font-size:11pt">.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 28.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Aunque no se han observado problemas renales con Biktarvy, existe la posibilidad de que pueda experimentar problemas renales si toma Biktarvy durante un periodo de tiempo prolongado.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Mientras est&#233; tomando este medicamento</span> <strong><span style="font-family:Times New Roman; font-size:11pt;">a&#250;n puede transmitir el VIH a los dem&#225;s,</span></strong> <span style="font-family:Times New Roman; font-size:11pt">aunque un tratamiento antirretroviral eficaz reduzca el riesgo. Consulte a su m&#233;dico sobre qu&#233; precauciones son necesarias para no infectar a otras personas. Este medicamento no es una cura para la infecci&#243;n por el VIH. Mientras usted est&#233; tomando Biktarvy podr&#225; seguir padeciendo infecciones u otras enfermedades asociadas con la infecci&#243;n por el VIH.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Ni&#241;os y adolescentes</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 17.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">No administre este medicamento a ni&#241;os y adolescentes menores de 18 a&#241;os de edad.</span></strong> <span style="font-family:Times New Roman; font-size:11pt">No se ha</span> <span style="font-family:Times New Roman; font-size:11pt">estudiado todav&#237;a el uso de Biktarvy en ni&#241;os y adolescentes menores de 18 a&#241;os de edad.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Otros medicamentos y Biktarvy</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 9.4pt 0pt 0.1pt; text-indent:0.05pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Informe a su m&#233;dico o farmac&#233;utico si est&#225; tomando, ha tomado recientemente o pudiera tener que tomar cualquier otro medicamento.</span></strong> <span style="font-family:Times New Roman; font-size:11pt">Biktarvy puede interaccionar con otros medicamentos.</span> <span style="font-family:Times New Roman; font-size:11pt">Como consecuencia, los niveles sangu&#237;neos de Biktarvy o de otros medicamentos se pueden ver afectados. Esto puede impedir que sus medicamentos funcionen correctamente o empeorar sus posibles efectos adversos. En algunos casos, su m&#233;dico puede tener que ajustar la dosis o comprobar sus concentraciones sangu&#237;neas.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><a name="page3" id="page3"></a><strong><span style="font-family:Times New Roman; font-size:11pt;">Medicamentos que nunca se deben tomar con Biktarvy:</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">rifampicina</span></strong> <span style="font-family:Times New Roman; font-size:11pt">utilizada para tratar algunas infecciones bacterianas como la tuberculosis</span></li><li style="margin:0pt 27pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">hierba de San Juan</span></strong> <span style="font-family:Times New Roman; font-size:11pt">(</span><em><span style="font-family:Times New Roman; font-size:11pt;">Hypericum perforatum</span></em><span style="font-family:Times New Roman; font-size:11pt">, hip&#233;rico), un medicamento a base de plantas</span> <span style="font-family:Times New Roman; font-size:11pt">utilizado para la depresi&#243;n y la ansiedad, o productos que lo contengan</span><strong><span style="font-family:Times New Roman; font-size:11pt;">.</span></strong></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 40pt 0pt 14.1pt; text-indent:0pt; text-align:justify; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si est&#225; tomando alguno de estos medicamentos,</span> <strong><span style="font-family:Times New Roman; font-size:11pt;">no tome Biktarvy e informe a su m&#233;dico</span></strong> <strong><span style="font-family:Times New Roman; font-size:11pt;">inmediatamente.</span></strong></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Consulte con su m&#233;dico si est&#225; tomando:</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">medicamentos utilizados para tratar el VIH y/o la hepatitis B</span></strong> <span style="font-family:Times New Roman; font-size:11pt">que contengan:</span></li><li style="list-style: none; display: inline"><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 53pt 0pt 37.06pt; text-indent:0pt; text-align:justify; padding-left:17.04pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">adefovir dipivoxil, atazanavir, bictegravir, emtricitabina, lamivudina, tenofovir alafenamida o tenofovir disoproxilo</span></li></ul></li><li style="margin:0pt 0pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">antibi&#243;ticos, utilizados para tratar las infecciones bacterianas</span></strong><span style="font-family:Times New Roman; font-size:11pt">, que contengan:</span></li><li style="list-style: none; display: inline"><div type="square" style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul type="square" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 44.66pt; text-indent:0pt; text-align:justify; padding-left:9.44pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">azitromicina, claritromicina, rifabutina o rifapentina</span></li></ul></div></li><li style="margin:0pt 0pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">antiepil&#233;pticos,</span></strong> <span style="font-family:Times New Roman; font-size:11pt">utilizados para tratar la epilepsia, que contengan:</span></li><li style="list-style: none; display: inline"><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 37.06pt; text-indent:0pt; text-align:justify; padding-left:17.04pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">carbamazepina, oxcarbazepina, fenobarbital o fenito&#237;na</span></li></ul></li><li style="margin:0pt 22pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">inmunosupresores,</span></strong> <span style="font-family:Times New Roman; font-size:11pt">utilizados para controlar la respuesta inmunitaria del organismo tras un</span> <span style="font-family:Times New Roman; font-size:11pt">trasplante, que contengan ciclosporina</span></li><li style="margin:0pt 0pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">medicamentos para la curaci&#243;n de &#250;lceras</span></strong> <span style="font-family:Times New Roman; font-size:11pt">que contengan sucralfato</span></li></ul><p style="margin:0pt 0pt 0pt 28.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 42pt 0pt 14.1pt; text-indent:0pt; text-align:justify; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Informe a su m&#233;dico si est&#225; tomando alguno de estos medicamentos.</span></strong> <span style="font-family:Times New Roman; font-size:11pt">No interrumpa su</span> <span style="font-family:Times New Roman; font-size:11pt">tratamiento sin consultar con su m&#233;dico.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Consulte a su m&#233;dico o farmac&#233;utico si est&#225; tomando:</span></strong></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 24pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">anti&#225;cidos</span></strong> <span style="font-family:Times New Roman; font-size:11pt">para tratar &#250;lceras estomacales, acidez estomacal o reflujo &#225;cido, que contengan</span> <span style="font-family:Times New Roman; font-size:11pt">hidr&#243;xido de aluminio y/o de magnesio</span></li><li style="margin:0pt 0pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">suplementos de minerales</span></strong> <span style="font-family:Times New Roman; font-size:11pt">o</span> <strong><span style="font-family:Times New Roman; font-size:11pt;">de vitaminas,</span></strong> <span style="font-family:Times New Roman; font-size:11pt">que contengan magnesio o hierro</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><div type="circle" style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 9pt 0pt 14.1pt; text-indent:0pt; text-align:justify; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Consulte a su m&#233;dico o farmac&#233;utico antes de tomar Biktarvy</span></strong> <span style="font-family:Times New Roman; font-size:11pt">si est&#225; tomando alguno de estos</span> <span style="font-family:Times New Roman; font-size:11pt">medicamentos.</span></li></ul></div><p style="margin:0pt 3pt 0pt 14.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Anti&#225;cidos y suplementos de magnesio:</span></strong> <span style="font-family:Times New Roman; font-size:11pt">tendr&#225; que tomar Biktarvy al menos 2 horas</span> <strong><span style="font-family:Times New Roman; font-size:11pt;">antes</span></strong> <span style="font-family:Times New Roman; font-size:11pt">de</span> <span style="font-family:Times New Roman; font-size:11pt">tomar los anti&#225;cidos o suplementos que contengan aluminio y/o magnesio. O puede tomar Biktarvy junto con alimentos al menos 2 horas</span> <strong><span style="font-family:Times New Roman; font-size:11pt;">despu&#233;s</span></strong> <span style="font-family:Times New Roman; font-size:11pt">de la toma del anti&#225;cido o suplemento que contenga aluminio y/o magnesio.</span></p><p style="margin:0pt 51pt 0pt 14.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Suplementos de hierro:</span></strong> <span style="font-family:Times New Roman; font-size:11pt">tendr&#225; que tomar Biktarvy al menos 2 horas</span> <strong><span style="font-family:Times New Roman; font-size:11pt;">antes</span></strong> <span style="font-family:Times New Roman; font-size:11pt">de tomar los</span> <span style="font-family:Times New Roman; font-size:11pt">suplementos de hierro o puede tomarlos todos juntos con alimentos.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Embarazo y lactancia</span></strong></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si est&#225; embarazada o en periodo de lactancia, cree que podr&#237;a estar embarazada o tiene intenci&#243;n de quedarse embarazada, consulte a su m&#233;dico o farmac&#233;utico antes de utilizar este medicamento.</span></li><li style="margin:0pt 25pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Informe a su m&#233;dico inmediatamente si se queda embarazada y pregunte sobre los posibles beneficios y riesgos de su tratamiento antirretroviral para usted y para su hijo.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 5pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si ha tomado Biktarvy durante su embarazo su m&#233;dico puede solicitar que se haga an&#225;lisis de sangre peri&#243;dicos y otras pruebas diagn&#243;sticas para controlar el desarrollo de su ni&#241;o. En ni&#241;os cuyas madres tomaron nucle&#243;sidos inhibidores de la transcriptasa inversa (ITIAN) durante el embarazo, el beneficio de la protecci&#243;n frente al VIH fue mayor que el riesgo de que se produjeran efectos adversos.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 10pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">No d&#233; el pecho a su hijo durante el tratamiento con Biktarvy.</span></strong> <span style="font-family:Times New Roman; font-size:11pt">Esto se debe a que algunos de los</span> <span style="font-family:Times New Roman; font-size:11pt">principios activos de este medicamento pasan a la leche materna. Se recomienda que no d&#233; el pecho para evitar que transmita el virus al ni&#241;o a trav&#233;s de la leche materna. Si realmente desea amamantar, hable primero con su m&#233;dico.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><a name="page4" id="page4"></a><strong><span style="font-family:Times New Roman; font-size:11pt;">Conducci&#243;n y uso de m&#225;quinas</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 26.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Biktarvy puede causar mareo. Si nota mareo durante el tratamiento con Biktarvy, no conduzca ni maneje herramientas o m&#225;quinas.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Biktarvy contiene sodio</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 60.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Este medicamento contiene menos de 1 mmol de sodio (23 mg) por comprimido; esto es, esencialmente &#8220;exento de sodio&#8221;.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p></div>
            </text>
          </section>
          <section>
            <title value="3. How to take 2"/>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/rmswi/"/>
                <code value="100000155538"/>
              </coding>
              <text value="3. How to take 2"/>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Siga exactamente las instrucciones de administraci&#243;n de este medicamento indicadas por su m&#233;dico.</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">En caso de duda, consulte de nuevo a su m&#233;dico o farmac&#233;utico.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">La dosis recomendada es:</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 224.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Adultos:</span></strong> <span style="font-family:Times New Roman; font-size:11pt">un comprimido al d&#237;a, con o sin alimentos</span></p><p style="margin:0pt 224.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No mastique, triture ni divida el comprimido.</span></p><p style="margin:0pt 224.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 14.1pt; text-indent:0pt; text-align:justify; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Consulte a su m&#233;dico o farmac&#233;utico si est&#225; tomando:</span></strong></li></ul><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 22.4pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">anti&#225;cidos</span></strong> <span style="font-family:Times New Roman; font-size:11pt">para tratar &#250;lceras estomacales, acidez estomacal o reflujo &#225;cido, que contengan</span> <span style="font-family:Times New Roman; font-size:11pt">hidr&#243;xido de aluminio y/o de magnesio</span></li><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; text-align:justify; padding-left:19.2pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">suplementos de minerales</span></strong> <span style="font-family:Times New Roman; font-size:11pt">o</span> <strong><span style="font-family:Times New Roman; font-size:11pt;">vitaminas</span></strong> <span style="font-family:Times New Roman; font-size:11pt">que contengan magnesio o hierro</span></li></ul><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 14.1pt; text-indent:0pt; text-align:justify; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Vea la secci&#243;n 2 para m&#225;s informaci&#243;n</span></strong> <span style="font-family:Times New Roman; font-size:11pt">sobre c&#243;mo tomar estos medicamentos con Biktarvy.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si toma m&#225;s Biktarvy del que debe</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si toma m&#225;s cantidad de la dosis recomendada de Biktarvy puede correr mayor riesgo de experimentar posibles efectos adversos con este medicamento (ver secci&#243;n 4,</span> <em><span style="font-family:Times New Roman; font-size:11pt;">Posibles efectos adversos</span></em><span style="font-family:Times New Roman; font-size:11pt">).</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 6.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Consulte inmediatamente a su m&#233;dico o acuda al servicio de urgencias m&#225;s cercano. Lleve consigo el frasco de comprimidos para que pueda describir f&#225;cilmente qu&#233; ha tomado.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si olvid&#243; tomar Biktarvy</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Es importante que no olvide una dosis de Biktarvy.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si olvida una dosis:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 1.4pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si se da cuenta en las 18 horas</span></strong> <span style="font-family:Times New Roman; font-size:11pt">posteriores a la hora a la que normalmente toma Biktarvy, debe</span> <span style="font-family:Times New Roman; font-size:11pt">tomar el comprimido tan pronto como sea posible. Luego tome la dosis siguiente de la forma habitual.</span></li><li style="margin:0pt 2.4pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si se da cuenta despu&#233;s de 18 horas o m&#225;s</span></strong> <span style="font-family:Times New Roman; font-size:11pt">de la hora a la que normalmente toma Biktarvy, no</span> <span style="font-family:Times New Roman; font-size:11pt">tome la dosis olvidada. Espere y tome la siguiente dosis a la hora habitual.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 22.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si vomita</span></strong> <span style="font-family:Times New Roman; font-size:11pt">antes de que transcurra 1 hora tras haber tomado Biktarvy, tome otro comprimido. Si</span> <span style="font-family:Times New Roman; font-size:11pt">vomita transcurrida 1 hora de haber tomado Biktarvy, no necesita tomar otro comprimido hasta el momento de la hora habitual.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">No interrumpa el tratamiento con Biktarvy</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 5.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">No interrumpa el tratamiento con Biktarvy sin hablar antes con su m&#233;dico.</span></strong> <span style="font-family:Times New Roman; font-size:11pt">Interrumpir Biktarvy</span> <span style="font-family:Times New Roman; font-size:11pt">puede afectar gravemente el funcionamiento de tratamientos futuros. Si se interrumpe Biktarvy por alg&#250;n motivo, consulte con su m&#233;dico antes de reiniciar la toma de comprimidos de Biktarvy.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 2.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><a name="page5" id="page5"></a><strong><span style="font-family:Times New Roman; font-size:11pt;">Cuando vea que le queda poca cantidad de Biktarvy,</span></strong> <span style="font-family:Times New Roman; font-size:11pt">acuda a su m&#233;dico o farmac&#233;utico para que le</span> <span style="font-family:Times New Roman; font-size:11pt">proporcione m&#225;s. Esto es muy importante, ya que la cantidad de virus puede empezar a aumentar si el medicamento se interrumpe incluso durante un corto periodo de tiempo. Es posible que entonces la enfermedad se vuelva m&#225;s dif&#237;cil de tratar.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 2.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si tiene infecci&#243;n por VIH y hepatitis B</span></strong> <span style="font-family:Times New Roman; font-size:11pt">es especialmente importante no suspender su tratamiento</span> <span style="font-family:Times New Roman; font-size:11pt">con Biktarvy sin antes hablar con su m&#233;dico. Puede necesitar hacerse an&#225;lisis de sangre durante varios meses tras suspender el tratamiento. En algunos pacientes con enfermedad hep&#225;tica avanzada o cirrosis no se recomienda suspender el tratamiento ya que esto puede producir un empeoramiento de su hepatitis, situaci&#243;n que puede ser potencialmente mortal.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 13.4pt 0pt 14.1pt; text-indent:0pt; text-align:justify; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Hable con su m&#233;dico inmediatamente</span></strong> <span style="font-family:Times New Roman; font-size:11pt">acerca de s&#237;ntomas nuevos o inusuales tras suspender su</span> <span style="font-family:Times New Roman; font-size:11pt">tratamiento, particularmente s&#237;ntomas que asocie con la infecci&#243;n por el virus de la hepatitis B.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si tiene cualquier otra duda sobre el uso de este medicamento, pregunte a su m&#233;dico o farmac&#233;utico.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p></div>
            </text>
          </section>
          <section>
            <title value="4. Possible side effects"/>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/rmswi/"/>
                <code value="100000155538"/>
              </coding>
              <text value="4. Possible side effects"/>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:12.75pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 9.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Al igual que todos los medicamentos, este medicamento puede producir efectos adversos, aunque no todas las personas los sufran.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Posibles efectos adversos: informe a un m&#233;dico inmediatamente</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 5.4pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Cualquier signo de inflamaci&#243;n o de infecci&#243;n.</span></strong> <span style="font-family:Times New Roman; font-size:11pt">En algunos pacientes con infecci&#243;n avanzada</span> <span style="font-family:Times New Roman; font-size:11pt">por el VIH (sida) y antecedentes de infecciones oportunistas (infecciones que ocurren en personas con un sistema inmunitario d&#233;bil), se pueden producir signos y s&#237;ntomas de inflamaci&#243;n por infecciones previas poco despu&#233;s de iniciar el tratamiento contra el VIH. Se cree que estos s&#237;ntomas se deben a una mejor&#237;a de la respuesta inmunitaria del organismo, que le permite combatir infecciones que podr&#237;an haber estado presentes sin s&#237;ntomas obvios.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 7.4pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Se pueden producir tambi&#233;n</span> <strong><span style="font-family:Times New Roman; font-size:11pt;">trastornos autoinmunitarios,</span></strong> <span style="font-family:Times New Roman; font-size:11pt">en los que el sistema inmunitario ataca a los tejidos sanos del organismo, despu&#233;s de que empiece a tomar medicamentos para la infecci&#243;n por el VIH. Los trastornos autoinmunitarios se pueden producir muchos meses despu&#233;s del inicio del tratamiento. Est&#233; atento a cualquier s&#237;ntoma de infecci&#243;n u otros s&#237;ntomas, como:</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><div type="circle" style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; text-align:justify; padding-left:20.09pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">debilidad muscular</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; text-align:justify; padding-left:20.09pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">debilidad que se inicia en las manos y los pies y se desplaza hacia el tronco</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; text-align:justify; padding-left:20.09pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">palpitaciones, temblor o hiperactividad</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 5.4pt 0pt 14.1pt; text-indent:0pt; text-align:justify; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si nota cualquiera de estos s&#237;ntomas o cualquier s&#237;ntoma de inflamaci&#243;n o infecci&#243;n, informe a su m&#233;dico inmediatamente.</span></strong></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Efectos adversos frecuentes</span></strong></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">(pueden afectar hasta 1 de cada 10 personas)</span></em></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">depresi&#243;n</span></li><li style="margin:0pt 0pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">sue&#241;os anormales</span></li><li style="margin:0pt 0pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dolor de cabeza</span></li><li style="margin:0pt 0pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">mareo</span></li><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; text-align:justify; padding-left:19.2pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">diarrea</span></li><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; text-align:justify; padding-left:19.2pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">ganas de vomitar (</span><em><span style="font-family:Times New Roman; font-size:11pt;">n&#225;useas</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; text-align:justify; padding-left:19.2pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">cansancio (</span><em><span style="font-family:Times New Roman; font-size:11pt;">fatiga</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Efectos adversos poco frecuentes</span></strong></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">(</span><em><span style="font-family:Times New Roman; font-size:11pt;">pueden afectar hasta 1 de cada 100 personas</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; text-align:justify; padding-left:19.2pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">anemia</span></li></ul><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.85pt; text-indent:0pt; padding-left:19.25pt; font-family:serif; font-size:11pt"><a name="page6" id="page6"></a><span style="font-family:Times New Roman; font-size:11pt">v&#243;mitos</span></li></ul><p style="margin:0pt; line-height:0.7pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; padding-left:19.2pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dolor de est&#243;mago</span></li></ul><p style="margin:0pt; line-height:0.7pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; padding-left:19.2pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">problemas digestivos que generan molestias despu&#233;s de las comidas (</span><em><span style="font-family:Times New Roman; font-size:11pt;">dispepsia</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li></ul><p style="margin:0pt; line-height:0.7pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; padding-left:19.2pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">gases (</span><em><span style="font-family:Times New Roman; font-size:11pt;">flatulencia</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li></ul><p style="margin:0pt; line-height:0.7pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; padding-left:19.2pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">hinchaz&#243;n de la cara, labios, lengua o garganta (</span><em><span style="font-family:Times New Roman; font-size:11pt;">angioedema</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li></ul><p style="margin:0pt; line-height:0.7pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; padding-left:19.2pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">picaz&#243;n (</span><em><span style="font-family:Times New Roman; font-size:11pt;">prurito</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li></ul><p style="margin:0pt; line-height:0.7pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; padding-left:19.2pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">erupci&#243;n</span></li></ul><p style="margin:0pt; line-height:0.7pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; padding-left:19.2pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">habones (</span><em><span style="font-family:Times New Roman; font-size:11pt;">urticaria</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li></ul><p style="margin:0pt; line-height:0.7pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; padding-left:19.2pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dolor en las articulaciones (</span><em><span style="font-family:Times New Roman; font-size:11pt;">artralgia</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li></ul><p style="margin:0pt; line-height:0.7pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; padding-left:19.2pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">comportamiento suicida</span></li></ul><p style="margin:0pt; line-height:0.7pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; padding-left:19.2pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">ansiedad</span></li></ul><p style="margin:0pt; line-height:0.7pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.9pt; text-indent:0pt; padding-left:19.2pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">trastornos del sue&#241;o</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Los an&#225;lisis de sangre tambi&#233;n pueden mostrar:</span></em></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 65pt; text-indent:-65pt; text-align:justify; font-family:serif; font-size:11pt; list-style-position:inside"><span style="font:7.0pt Times New Roman">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</span> <span style="font-family:Times New Roman; font-size:11pt">Concentraciones m&#225;s altas de sustancias llamadas bilirrubina y/o creatinina s&#233;rica en la sangre</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 28.4pt 0pt 65pt; text-indent:-65pt; text-align:justify; font-family:serif; font-size:11pt; list-style-position:inside"><span style="font:7.0pt Times New Roman">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</span> <strong><span style="font-family:Times New Roman; font-size:11pt;">Si considera que alguno de los efectos adversos que sufre es grave, informe a su m&#233;dico.</span></strong></li></ul><p style="margin:0pt 28.4pt 0pt 0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Otros efectos que se pueden observar durante el tratamiento contra el VIH</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 11.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La frecuencia de los siguientes efectos adversos se considera no conocida (la frecuencia no se puede estimar a partir de los datos disponibles).</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 2.4pt 0pt 8.85pt; text-indent:0pt; text-align:justify; padding-left:19.25pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Problemas &#243;seos.</span></strong> <span style="font-family:Times New Roman; font-size:11pt">Algunos pacientes tratados con medicamentos antirretrovirales combinados</span> <span style="font-family:Times New Roman; font-size:11pt">como Biktarvy pueden desarrollar una enfermedad de los huesos llamada</span> <em><span style="font-family:Times New Roman; font-size:11pt;">osteonecrosis</span></em> <span style="font-family:Times New Roman; font-size:11pt">(muerte del tejido &#243;seo debida a una p&#233;rdida del suministro de sangre al hueso). Tomar este tipo de medicamentos durante un tiempo prolongado, tomar corticosteroides, beber alcohol, tener un sistema inmunitario muy d&#233;bil y tener sobrepeso, pueden ser algunos de los muchos factores de riesgo para desarrollar esta enfermedad. Los signos de osteonecrosis son:</span></li><li style="list-style: none; display: inline"><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; text-align:justify; padding-left:20.09pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">rigidez articular</span></li><li style="margin:0pt 0pt 0pt 36.96pt; text-indent:0pt; text-align:justify; padding-left:20.14pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">molestias y dolores articulares (especialmente de la cadera, la rodilla y el hombro)</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; text-align:justify; padding-left:20.09pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dificultad para moverse</span></li></ul></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 14.1pt; text-indent:0pt; text-align:justify; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si nota cualquiera de estos s&#237;ntomas, informe a su m&#233;dico.</span></strong></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 12.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Durante el tratamiento del VIH puede haber un aumento en el peso y en los niveles de glucosa y l&#237;pidos en la sangre. Esto puede estar en parte relacionado con la recuperaci&#243;n de la salud y con el estilo de vida y, en el caso de los l&#237;pidos en la sangre, algunas veces con los medicamentos contra el VIH por s&#237; mismos. Su m&#233;dico le controlar&#225; estos cambios.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Comunicaci&#243;n de efectos adversos</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 17.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si experimenta cualquier tipo de efecto adverso, consulte a su m&#233;dico o farmac&#233;utico, incluso si se trata de posibles efectos adversos que no aparecen en este prospecto. Tambi&#233;n puede comunicarlos directamente</span> <span style="font-family:Times New Roman; font-size:11pt; background-color:#c0c0c0">a trav&#233;s del sistema nacional de notificaci&#243;n incluido en el</span> <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="font-family:Times New Roman; font-size:11pt; background-color:#c0c0c0">Ap&#233;ndice V.</span></a> <span style="font-family:Times New Roman; font-size:11pt">Mediante la comunicaci&#243;n de efectos adversos usted puede contribuir a proporcionar m&#225;s informaci&#243;n sobre la seguridad de este medicamento.</span></p><p style="margin:0pt 17.4pt 0pt 0.1pt; text-align:justify; line-height:104%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p></div>
            </text>
          </section>
          <section>
            <title value="5. How to store 2"/>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/rmswi/"/>
                <code value="100000155538"/>
              </coding>
              <text value="5. How to store 2"/>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Mantener este medicamento fuera de la vista y del alcance de los ni&#241;os.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 17.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No utilice este medicamento despu&#233;s de la fecha de caducidad que aparece en la caja y en el frasco despu&#233;s de {CAD}. La fecha de caducidad es el &#250;ltimo d&#237;a del mes que se indica.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 14.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Conservar en el embalaje original para protegerlo de la humedad. Mantener el frasco perfectamente cerrado. No utilizar si falta el sello del frasco o est&#225; roto.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 5.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><a name="page7" id="page7"></a><span style="font-family:Times New Roman; font-size:11pt">Los medicamentos no se deben tirar por los desag&#252;es ni a la basura. Pregunte a su farmac&#233;utico c&#243;mo deshacerse de los envases y de los medicamentos que ya no necesita. De esta forma, ayudar&#225; a proteger el medio ambiente.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p></div>
            </text>
          </section>
          <section>
            <title value="6. Contents of the pack and other information"/>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/rmswi/"/>
                <code value="100000155538"/>
              </coding>
              <text value="6. Contents of the pack and other information"/>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:0.05pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 12.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Composici&#243;n de Biktarvy</span></strong></p><p style="margin:0pt 12.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">&#xa0;</span></strong></p><p style="margin:0pt 12.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Los principios activos son</span></strong> <span style="font-family:Times New Roman; font-size:11pt">bictegravir, emtricitabina y tenofovir alafenamida. Cada comprimido de</span> <span style="font-family:Times New Roman; font-size:11pt">Biktarvy contiene bictegravir s&#243;dico equivalente a 50 mg de bictegravir, 200 mg de emtricitabina y tenofovir alafenamida fumarato equivalente a 25 mg de tenofovir alafenamida.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Los dem&#225;s componentes son</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">N&#250;cleo del comprimido</span></em></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Celulosa microcristalina, croscarmelosa s&#243;dica, estearato de magnesio.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Recubrimiento con pel&#237;cula</span></em></p><p style="margin:0pt 3.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Alcohol polivin&#237;lico, di&#243;xido de titanio (E171), macrogol, talco, &#243;xido de hierro rojo (E172), &#243;xido de hierro negro (E172).</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Aspecto del producto y contenido del envase</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 10.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Los comprimidos recubiertos con pel&#237;cula de Biktarvy son comprimidos recubiertos con pel&#237;cula de color marr&#243;n purp&#250;reo, con forma de c&#225;psula, marcados en una de las caras del comprimido con &#171;GSI&#187; y en la otra cara del comprimido con &#171;9883&#187;. Biktarvy se presenta en frascos de 30 comprimidos y en envases de 3 frascos, conteniendo cada uno de ellos 30 comprimidos. Cada frasco contiene un desecante de gel de s&#237;lice que debe conservarse en el frasco para ayudar a proteger los comprimidos. El desecante de gel de s&#237;lice est&#225; contenido en un sobre o recipiente separado, y no se debe tragar.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Puede que solamente est&#233;n comercializados algunos tama&#241;os de envases.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Titular de la autorizaci&#243;n de comercializaci&#243;n</span></strong></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Carrigtohill</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">County Cork, T45 DP77</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Irlanda</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Responsable de la fabricaci&#243;n</span></strong></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">IDA Business &#38; Technology Park</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Carrigtohill</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">County Cork</span></p><p style="margin:0pt 0pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Irlanda</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 6.4pt 0pt 0.1pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Pueden solicitar m&#225;s informaci&#243;n respecto a este medicamento dirigi&#233;ndose al representante local del titular de la autorizaci&#243;n de comercializaci&#243;n:</span></p><p style="margin:0pt; line-height:8.5pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Belgi&#235;/Belgique/Belgien</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Belgium SPRL-BVBA</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">T&#233;l/Tel: + 32 (0) 24 01 35 50</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Lietuva</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Poland Sp. z o.o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel.: + 48 (0) 22 262 8702</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">????????</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">???.: + 353 (0) 1 686 1888</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Luxembourg/Luxemburg</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Belgium SPRL-BVBA</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">T&#233;l/Tel: + 32 (0) 24 01 35 50</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Cesk&#225; republika</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences s.r.o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 420 (0) 910 871 986</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Magyarorsz&#225;g</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences</span> <span style="font-family:Times New Roman; font-size:11pt">Ireland UC</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel.: + 353 (0) 1 686 1888</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Danmark</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Sweden AB</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tlf: + 46 (0) 8 5057 1849</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Malta</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 353 (0) 1 686 1888</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Deutschland</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences GmbH</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 49 (0) 89 899890-0</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Nederland</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Netherlands B.V.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 31 (0) 20 718 36 98</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Eesti</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Poland Sp. z o.o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel.: +48 (0) 22 262 8702</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Norge</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Sweden AB</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tlf: + 46 (0) 8 5057 1849</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">&#917;&#955;&#955;?&#948;&#945;</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences &#917;&#955;&#955;?&#962; &#924;.&#917;&#928;&#917;.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#932;&#951;&#955;: + 30 (0) 210 8930 100</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">&#214;sterreich</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences GesmbH</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 43 (0) 1 260 830</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Espa&#241;a</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences, S.L.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 34 (0) 91 378 98 30</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Polska</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Poland Sp. z o.o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel.: + 48 (0) 22 262 870</span><span style="font-family:Times New Roman; font-size:11pt">2</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">France</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">T&#233;l: + 33 (0) 1 46 09 41 00</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Portugal</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences, Lda.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 351 (0) 21 7928790</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Hrvatska</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 353 (0) 1 686 1888</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Rom&#226;nia</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 353 (0) 1 686 1888</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Irlanda</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 353 (0) 214 825 999</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Slovenija</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 353 (0) 1 686 1888</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">&#205;sland</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Sweden AB</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">S&#237;mi: + 46 (0) 8 5057 1849</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Slovensk&#225; republika</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Slovakia s.r.o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 421 (0) 232 121 210</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Italia</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences S.r.l.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 39 02 439201</span></p><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">&#xa0;</span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Suomi/Finland</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Sweden AB</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Puh/Tel: + 46 (0) 8 5057 1849</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">&#922;?&#960;&#961;&#959;&#962;</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences &#917;&#955;&#955;?&#962; &#924;.&#917;&#928;&#917;.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">&#932;&#951;&#955;: + 30 (0) 210 8930 100</span></p><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">&#xa0;</span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Sverige</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Sweden A</span><span style="font-family:Times New Roman; font-size:11pt">B</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 46 (0) 8 5057 1849</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Latvija</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Poland Sp. z o.o.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel.: + 48 (0) 22 262 8702</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:216.1pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Reino Unido</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ltd.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 44 (0) 8000 113 700</span></p></td></tr></table><p style="margin:0pt; line-height:7.5pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt; line-height:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><a name="page9" id="page9"></a><strong><span style="font-family:Times New Roman; font-size:11pt;">Fecha de la &#250;ltima revisi&#243;n de este prospecto:</span></strong></p><p style="margin:0pt; line-height:12.8pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt 38.4pt 0pt 0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La informaci&#243;n detallada de este medicamento est&#225; disponible en la p&#225;gina web de la Agencia Europea de Medicamentos:</span> <a href="http://www.ema.europa.eu/"><span style="font-family:Times New Roman; font-size:11pt">http://www.ema.europa.eu.</span></a></p><p style="margin:0pt; line-height:10pt"><span style="font-family:Times New Roman; font-size:10pt">&#xa0;</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&#xa0;</span></p></div>
            </text>
          </section>
        </section>
      </Composition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/ClinicalUseDefinition/cud-d79af6e660f456c6c7091803d6bd1a92"/>
    <resource>
      <ClinicalUseDefinition>
        <id value="cud-d79af6e660f456c6c7091803d6bd1a92"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-contraindication-uv-epi"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: ClinicalUseDefinition</b><a name="cud-d79af6e660f456c6c7091803d6bd1a92"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource ClinicalUseDefinition &quot;cud-d79af6e660f456c6c7091803d6bd1a92&quot; </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-ClinicalUseDefinition-contraindication-uv-epi.html">ClinicalUseDefinition Contraindication (ePI)</a></p></div><p><b>identifier</b>: id:Â pregnancyÂ (use:Â OFFICIAL)</p><p><b>type</b>: contraindication</p><p><b>subject</b>: <a href="#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></p><blockquote><p><b>contraindication</b></p><h3>DiseaseSymptomProcedures</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td>nan <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (mdr#nan)</span></td></tr></table></blockquote></div>
        </text>
        <identifier>
          <use value="official"/>
          <system value="https://spor.ema.europa.eu/rmswi/#/"/>
          <value value="pregnancy"/>
        </identifier>
        <type value="contraindication"/>
        <subject>
          <reference value="MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"/>
        </subject>
        <contraindication>
          <diseaseSymptomProcedure>
            <concept>
              <coding>
                <system value="http://terminology.hl7.org/CodeSystem/mdr"/>
                <code value="nan"/>
                <display value="nan"/>
              </coding>
            </concept>
          </diseaseSymptomProcedure>
        </contraindication>
      </ClinicalUseDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-biktarvy-bictegravirsodium"/>
    <resource>
      <Ingredient>
        <id value="ingredient-for-biktarvy-bictegravirsodium"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Ingredient</b><a name="ingredient-for-biktarvy-bictegravirsodium"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Ingredient &quot;ingredient-for-biktarvy-bictegravirsodium&quot; </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Ingredient-uv-epi.html">Ingredient (ePI)</a></p></div><p><b>identifier</b>: id:Â 4L5MP1Y7W7Â (use:Â OFFICIAL)</p><p><b>status</b>: active</p><p><b>for</b>: </p><ul><li><a href="#ManufacturedItemDefinition_mid-94a96e39cfdcd8b378d12dd4063065f9">See above (ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9)</a></li><li><a href="#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></li><li><a href="#AdministrableProductDefinition_ap-94a96e39cfdcd8b378d12dd4063065f9">See above (AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9)</a></li></ul><p><b>role</b>: Active <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000072072)</span></p><blockquote><p><b>substance</b></p><h3>Codes</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td>BICTEGRAVIR SODIUM <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (beta#4L5MP1Y7W7)</span></td></tr></table><h3>Strengths</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Presentation[x]</b></td><td><b>Basis</b></td></tr><tr><td style="display: none">*</td><td>50 mg<span style="background: LightGoldenRodYellow"> (Details: UCUM code mg = 'mg')</span></td><td>active ingredient - basis of strength <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.3.0/CodeSystem-v3-RoleClass.html">RoleClass</a>#ACTIB)</span></td></tr></table></blockquote></div>
        </text>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
          <value value="4L5MP1Y7W7"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"/>
        </for>
        <for>
          <reference value="MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"/>
        </for>
        <for>
          <reference value="AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9"/>
        </for>
        <role>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="100000072072"/>
            <display value="Active"/>
          </coding>
        </role>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
                <code value="4L5MP1Y7W7"/>
                <display value="BICTEGRAVIR SODIUM"/>
              </coding>
            </concept>
          </code>
          <strength>
            <presentationQuantity>
              <value value="50"/>
              <system value="http://unitsofmeasure.org"/>
              <code value="mg"/>
            </presentationQuantity>
            <basis>
              <coding>
                <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
                <code value="ACTIB"/>
                <display value="active ingredient - basis of strength"/>
              </coding>
            </basis>
          </strength>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-biktarvy-emtricitabine"/>
    <resource>
      <Ingredient>
        <id value="ingredient-for-biktarvy-emtricitabine"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Ingredient</b><a name="ingredient-for-biktarvy-emtricitabine"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Ingredient &quot;ingredient-for-biktarvy-emtricitabine&quot; </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Ingredient-uv-epi.html">Ingredient (ePI)</a></p></div><p><b>identifier</b>: id:Â G70B4ETF4SÂ (use:Â OFFICIAL)</p><p><b>status</b>: active</p><p><b>for</b>: </p><ul><li><a href="#ManufacturedItemDefinition_mid-94a96e39cfdcd8b378d12dd4063065f9">See above (ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9)</a></li><li><a href="#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></li><li><a href="#AdministrableProductDefinition_ap-94a96e39cfdcd8b378d12dd4063065f9">See above (AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9)</a></li></ul><p><b>role</b>: Active <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000072072)</span></p><blockquote><p><b>substance</b></p><h3>Codes</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td>Emtricitabine <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (beta#G70B4ETF4S)</span></td></tr></table><h3>Strengths</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Presentation[x]</b></td><td><b>Basis</b></td></tr><tr><td style="display: none">*</td><td>200 mg<span style="background: LightGoldenRodYellow"> (Details: UCUM code mg = 'mg')</span></td><td>active ingredient - basis of strength <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.3.0/CodeSystem-v3-RoleClass.html">RoleClass</a>#ACTIB)</span></td></tr></table></blockquote></div>
        </text>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
          <value value="G70B4ETF4S"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"/>
        </for>
        <for>
          <reference value="MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"/>
        </for>
        <for>
          <reference value="AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9"/>
        </for>
        <role>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="100000072072"/>
            <display value="Active"/>
          </coding>
        </role>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
                <code value="G70B4ETF4S"/>
                <display value="Emtricitabine"/>
              </coding>
            </concept>
          </code>
          <strength>
            <presentationQuantity>
              <value value="200"/>
              <system value="http://unitsofmeasure.org"/>
              <code value="mg"/>
            </presentationQuantity>
            <basis>
              <coding>
                <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
                <code value="ACTIB"/>
                <display value="active ingredient - basis of strength"/>
              </coding>
            </basis>
          </strength>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-biktarvy-tenofoviralafenamide"/>
    <resource>
      <Ingredient>
        <id value="ingredient-for-biktarvy-tenofoviralafenamide"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Ingredient</b><a name="ingredient-for-biktarvy-tenofoviralafenamide"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Ingredient &quot;ingredient-for-biktarvy-tenofoviralafenamide&quot; </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Ingredient-uv-epi.html">Ingredient (ePI)</a></p></div><p><b>identifier</b>: id:Â EL9943AG5JÂ (use:Â OFFICIAL)</p><p><b>status</b>: active</p><p><b>for</b>: </p><ul><li><a href="#ManufacturedItemDefinition_mid-94a96e39cfdcd8b378d12dd4063065f9">See above (ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9)</a></li><li><a href="#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></li><li><a href="#AdministrableProductDefinition_ap-94a96e39cfdcd8b378d12dd4063065f9">See above (AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9)</a></li></ul><p><b>role</b>: Active <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000072072)</span></p><blockquote><p><b>substance</b></p><h3>Codes</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td>tenofovir alafenamide <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (beta#EL9943AG5J)</span></td></tr></table><h3>Strengths</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Presentation[x]</b></td><td><b>Basis</b></td></tr><tr><td style="display: none">*</td><td>25 mg<span style="background: LightGoldenRodYellow"> (Details: UCUM code mg = 'mg')</span></td><td>active ingredient - basis of strength <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.3.0/CodeSystem-v3-RoleClass.html">RoleClass</a>#ACTIB)</span></td></tr></table></blockquote></div>
        </text>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
          <value value="EL9943AG5J"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"/>
        </for>
        <for>
          <reference value="MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"/>
        </for>
        <for>
          <reference value="AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9"/>
        </for>
        <role>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="100000072072"/>
            <display value="Active"/>
          </coding>
        </role>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
                <code value="EL9943AG5J"/>
                <display value="tenofovir alafenamide"/>
              </coding>
            </concept>
          </code>
          <strength>
            <presentationQuantity>
              <value value="25"/>
              <system value="http://unitsofmeasure.org"/>
              <code value="mg"/>
            </presentationQuantity>
            <basis>
              <coding>
                <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
                <code value="ACTIB"/>
                <display value="active ingredient - basis of strength"/>
              </coding>
            </basis>
          </strength>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-biktarvy-microcrystallinecellulose"/>
    <resource>
      <Ingredient>
        <id value="ingredient-for-biktarvy-microcrystallinecellulose"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Ingredient</b><a name="ingredient-for-biktarvy-microcrystallinecellulose"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Ingredient &quot;ingredient-for-biktarvy-microcrystallinecellulose&quot; </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Ingredient-uv-epi.html">Ingredient (ePI)</a></p></div><p><b>identifier</b>: id:Â OP1R32D61UÂ (use:Â OFFICIAL)</p><p><b>status</b>: active</p><p><b>for</b>: </p><ul><li><a href="#ManufacturedItemDefinition_mid-94a96e39cfdcd8b378d12dd4063065f9">See above (ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9)</a></li><li><a href="#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></li><li><a href="#AdministrableProductDefinition_ap-94a96e39cfdcd8b378d12dd4063065f9">See above (AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9)</a></li></ul><p><b>role</b>: Excipient <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000072082)</span></p><blockquote><p><b>substance</b></p><h3>Codes</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td>Microcrystalline cellulose <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (beta#OP1R32D61U)</span></td></tr></table></blockquote></div>
        </text>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
          <value value="OP1R32D61U"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"/>
        </for>
        <for>
          <reference value="MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"/>
        </for>
        <for>
          <reference value="AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9"/>
        </for>
        <role>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
                <code value="OP1R32D61U"/>
                <display value="Microcrystalline cellulose"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-biktarvy-croscarmellosesodium"/>
    <resource>
      <Ingredient>
        <id value="ingredient-for-biktarvy-croscarmellosesodium"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Ingredient</b><a name="ingredient-for-biktarvy-croscarmellosesodium"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Ingredient &quot;ingredient-for-biktarvy-croscarmellosesodium&quot; </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Ingredient-uv-epi.html">Ingredient (ePI)</a></p></div><p><b>identifier</b>: id:Â M28OL1HH48Â (use:Â OFFICIAL)</p><p><b>status</b>: active</p><p><b>for</b>: </p><ul><li><a href="#ManufacturedItemDefinition_mid-94a96e39cfdcd8b378d12dd4063065f9">See above (ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9)</a></li><li><a href="#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></li><li><a href="#AdministrableProductDefinition_ap-94a96e39cfdcd8b378d12dd4063065f9">See above (AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9)</a></li></ul><p><b>role</b>: Excipient <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000072082)</span></p><blockquote><p><b>substance</b></p><h3>Codes</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td>Croscarmellose sodium <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (beta#M28OL1HH48)</span></td></tr></table></blockquote></div>
        </text>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
          <value value="M28OL1HH48"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"/>
        </for>
        <for>
          <reference value="MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"/>
        </for>
        <for>
          <reference value="AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9"/>
        </for>
        <role>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
                <code value="M28OL1HH48"/>
                <display value="Croscarmellose sodium"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/Ingredient/ingredient-for-biktarvy-magnesiumstearate"/>
    <resource>
      <Ingredient>
        <id value="ingredient-for-biktarvy-magnesiumstearate"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Ingredient</b><a name="ingredient-for-biktarvy-magnesiumstearate"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Ingredient &quot;ingredient-for-biktarvy-magnesiumstearate&quot; </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Ingredient-uv-epi.html">Ingredient (ePI)</a></p></div><p><b>identifier</b>: id:Â 70097M6I30Â (use:Â OFFICIAL)</p><p><b>status</b>: active</p><p><b>for</b>: </p><ul><li><a href="#ManufacturedItemDefinition_mid-94a96e39cfdcd8b378d12dd4063065f9">See above (ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9)</a></li><li><a href="#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></li><li><a href="#AdministrableProductDefinition_ap-94a96e39cfdcd8b378d12dd4063065f9">See above (AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9)</a></li></ul><p><b>role</b>: Excipient <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000072082)</span></p><blockquote><p><b>substance</b></p><h3>Codes</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td>Magnesium stearate <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (beta#70097M6I30)</span></td></tr></table></blockquote></div>
        </text>
        <identifier>
          <use value="official"/>
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
          <value value="70097M6I30"/>
        </identifier>
        <status value="active"/>
        <for>
          <reference value="ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"/>
        </for>
        <for>
          <reference value="MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"/>
        </for>
        <for>
          <reference value="AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9"/>
        </for>
        <role>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="100000072082"/>
            <display value="Excipient"/>
          </coding>
        </role>
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta"/>
                <code value="70097M6I30"/>
                <display value="Magnesium stearate"/>
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/AdministrableProductDefinition/ap-94a96e39cfdcd8b378d12dd4063065f9"/>
    <resource>
      <AdministrableProductDefinition>
        <id value="ap-94a96e39cfdcd8b378d12dd4063065f9"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/AdministrableProductDefinition-uv-epi"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: AdministrableProductDefinition</b><a name="ap-94a96e39cfdcd8b378d12dd4063065f9"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource AdministrableProductDefinition &quot;ap-94a96e39cfdcd8b378d12dd4063065f9&quot; </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-AdministrableProductDefinition-uv-epi.html">AdministrableProductDefinition (ePI)</a></p></div><p><b>identifier</b>: id:Â EU/1/18/1289/001</p><p><b>status</b>: active</p><p><b>formOf</b>: <a href="#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></p><p><b>administrableDoseForm</b>: Tablet <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000073664)</span></p><p><b>unitOfPresentation</b>: Tablet <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#200000002152)</span></p><p><b>producedFrom</b>: <a href="#ManufacturedItemDefinition_mid-94a96e39cfdcd8b378d12dd4063065f9">See above (ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9)</a></p><blockquote><p><b>routeOfAdministration</b></p><p><b>code</b>: Oral use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000073619)</span></p><h3>TargetSpecies</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td></tr><tr><td style="display: none">*</td><td>Human <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000109093)</span></td></tr></table></blockquote></div>
        </text>
        <identifier>
          <system value="https://spor.ema.europa.eu/pmswi"/>
          <value value="EU/1/18/1289/001"/>
        </identifier>
        <status value="active"/>
        <formOf>
          <reference value="MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"/>
        </formOf>
        <administrableDoseForm>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="100000073664"/>
            <display value="Tablet"/>
          </coding>
        </administrableDoseForm>
        <unitOfPresentation>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="200000002152"/>
            <display value="Tablet"/>
          </coding>
        </unitOfPresentation>
        <producedFrom>
          <reference value="ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"/>
        </producedFrom>
        <routeOfAdministration>
          <code>
            <coding>
              <system value="https://spor.ema.europa.eu/rmswi"/>
              <code value="100000073619"/>
              <display value="Oral use"/>
            </coding>
          </code>
          <targetSpecies>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/rmswi"/>
                <code value="100000109093"/>
                <display value="Human"/>
              </coding>
            </code>
          </targetSpecies>
        </routeOfAdministration>
      </AdministrableProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/RegulatedAuthorization/authorization94a96e39cfdcd8b378d12dd4063065f90"/>
    <resource>
      <RegulatedAuthorization>
        <id value="authorization94a96e39cfdcd8b378d12dd4063065f90"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/RegulatedAuthorization-uv-epi"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: RegulatedAuthorization</b><a name="authorization94a96e39cfdcd8b378d12dd4063065f90"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource RegulatedAuthorization &quot;authorization94a96e39cfdcd8b378d12dd4063065f90&quot; </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-RegulatedAuthorization-uv-epi.html">RegulatedAuthorization (ePI)</a></p></div><p><b>identifier</b>: id:Â EU/1/18/1289/001Â (use:Â OFFICIAL)</p><p><b>subject</b>: <a href="#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></p><p><b>type</b>: Marketing Authorisation <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#220000000061)</span></p><p><b>status</b>: Active <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-publication-status.html">PublicationStatus</a>#active)</span></p><p><b>statusDate</b>: 2018-06-21 13:28:17+0000</p><p><b>holder</b>: <a href="#Organization_mah-715f8a161ed438d0584510e5b4512caa">See above (Organization/mah-715f8a161ed438d0584510e5b4512caa)</a></p><p><b>regulator</b>: <a href="#Organization_mra-1133a7374c78f1d40f41885344f06a5a">See above (Organization/mra-1133a7374c78f1d40f41885344f06a5a)</a></p></div>
        </text>
        <identifier>
          <use value="official"/>
          <system value="https://spor.ema.europa.eu/pmswi"/>
          <value value="EU/1/18/1289/001"/>
        </identifier>
        <subject>
          <reference value="MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"/>
        </subject>
        <type>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="220000000061"/>
            <display value="Marketing Authorisation"/>
          </coding>
        </type>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status"/>
            <code value="active"/>
            <display value="Active"/>
          </coding>
        </status>
        <statusDate value="2018-06-21T13:28:17Z"/>
        <holder>
          <reference value="Organization/mah-715f8a161ed438d0584510e5b4512caa"/>
        </holder>
        <regulator>
          <reference value="Organization/mra-1133a7374c78f1d40f41885344f06a5a"/>
        </regulator>
      </RegulatedAuthorization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/Organization/mah-715f8a161ed438d0584510e5b4512caa"/>
    <resource>
      <Organization>
        <id value="mah-715f8a161ed438d0584510e5b4512caa"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Organization</b><a name="mah-715f8a161ed438d0584510e5b4512caa"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Organization &quot;mah-715f8a161ed438d0584510e5b4512caa&quot; </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Organization-uv-epi.html">Organization (ePI)</a></p></div><p><b>identifier</b>: id:Â ORG-100008368Â (use:Â OFFICIAL)</p><p><b>active</b>: true</p><p><b>type</b>: Marketing authorisation holder <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#220000000034)</span></p><p><b>name</b>: Gilead Sciences Ireland UC</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Address</b></td></tr><tr><td style="display: none">*</td><td>Carrigtohill, County Cork, T45 County Cork IR(WORK)</td></tr></table></div>
        </text>
        <identifier>
          <use value="official"/>
          <system value="https://spor.ema.europa.eu/omswi"/>
          <value value="ORG-100008368"/>
        </identifier>
        <active value="true"/>
        <type>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="220000000034"/>
            <display value="Marketing authorisation holder"/>
          </coding>
        </type>
        <name value="Gilead Sciences Ireland UC"/>
        <contact>
          <address>
            <use value="work"/>
            <type value="physical"/>
            <text value="Carrigtohill, County Cork, T45 County Cork IR"/>
            <line value="Carrigtohill, County Cork, T45"/>
            <city value="County Cork"/>
            <country value="IR"/>
          </address>
        </contact>
      </Organization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/Organization/mra-1133a7374c78f1d40f41885344f06a5a"/>
    <resource>
      <Organization>
        <id value="mra-1133a7374c78f1d40f41885344f06a5a"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Organization</b><a name="mra-1133a7374c78f1d40f41885344f06a5a"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Organization &quot;mra-1133a7374c78f1d40f41885344f06a5a&quot; </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-Organization-uv-epi.html">Organization (ePI)</a></p></div><p><b>identifier</b>: id:Â ORG-100013412Â (use:Â OFFICIAL)</p><p><b>active</b>: true</p><p><b>type</b>: Medicines Regulatory Authority <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#220000000032)</span></p><p><b>name</b>: European Medicines Agency</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Address</b></td></tr><tr><td style="display: none">*</td><td>Carretera De Martorell 41 61, Poligono Industrial Nord-Est Amsterdam NL(WORK)</td></tr></table></div>
        </text>
        <identifier>
          <use value="official"/>
          <system value="https://spor.ema.europa.eu/omswi"/>
          <value value="ORG-100013412"/>
        </identifier>
        <active value="true"/>
        <type>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="220000000032"/>
            <display value="Medicines Regulatory Authority"/>
          </coding>
        </type>
        <name value="European Medicines Agency"/>
        <contact>
          <address>
            <use value="work"/>
            <type value="physical"/>
            <text value="Carretera De Martorell 41 61, Poligono Industrial Nord-Est Amsterdam NL"/>
            <line value="Carretera De Martorell 41 61, Poligono Industrial Nord-Est"/>
            <city value="Amsterdam"/>
            <postalCode value="1083 HS"/>
            <country value="NL"/>
          </address>
        </contact>
      </Organization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/PackagedProductDefinition/ppd-e34e4b65abd3fd8e667db05606cc25a9"/>
    <resource>
      <PackagedProductDefinition>
        <id value="ppd-e34e4b65abd3fd8e667db05606cc25a9"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: PackagedProductDefinition</b><a name="ppd-e34e4b65abd3fd8e667db05606cc25a9"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource PackagedProductDefinition &quot;ppd-e34e4b65abd3fd8e667db05606cc25a9&quot; </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-PackagedProductDefinition-uv-epi.html">PackagedProductDefinition (ePI)</a></p></div><p><b>identifier</b>: id:Â EU/1/18/1289/001Â (use:Â OFFICIAL)</p><p><b>name</b>: Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion 90</p><p><b>type</b>: Chemical Medicinal Product <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000155527)</span></p><p><b>packageFor</b>: <a href="#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></p><p><b>status</b>: Active <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-publication-status.html">PublicationStatus</a>#active)</span></p><p><b>statusDate</b>: 2012-02-07 13:28:17+0000</p><blockquote><p><b>packaging</b></p><p><b>type</b>: Box <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000073498)</span></p><p><b>quantity</b>: 1</p><p><b>material</b>: Cardboard <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#200000003529)</span></p><blockquote><p><b>packaging</b></p><p><b>identifier</b>: id:Â 654321</p><p><b>type</b>: Child-resistant closure <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000073504)</span></p><p><b>quantity</b>: 90</p><p><b>material</b>: PolyVinyl Chloride <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#200000003222)</span></p><blockquote><p><b>containedItem</b></p></blockquote></blockquote></blockquote></div>
        </text>
        <identifier>
          <use value="official"/>
          <system value="https://spor.ema.europa.eu/pmswi"/>
          <value value="EU/1/18/1289/001"/>
        </identifier>
        <name value="Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion 90"/>
        <type>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="100000155527"/>
            <display value="Chemical Medicinal Product"/>
          </coding>
        </type>
        <packageFor>
          <reference value="MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"/>
        </packageFor>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status"/>
            <code value="active"/>
            <display value="Active"/>
          </coding>
        </status>
        <statusDate value="2012-02-07T13:28:17Z"/>
        <packaging>
          <type>
            <coding>
              <system value="https://spor.ema.europa.eu/rmswi"/>
              <code value="100000073498"/>
              <display value="Box"/>
            </coding>
          </type>
          <quantity value="1"/>
          <material>
            <coding>
              <system value="https://spor.ema.europa.eu/rmswi"/>
              <code value="200000003529"/>
              <display value="Cardboard"/>
            </coding>
          </material>
          <packaging>
            <identifier>
              <system value="https://spor.ema.europa.eu/pmswi"/>
              <value value="654321"/>
            </identifier>
            <type>
              <coding>
                <system value="https://spor.ema.europa.eu/rmswi"/>
                <code value="100000073504"/>
                <display value="Child-resistant closure"/>
              </coding>
            </type>
            <quantity value="90"/>
            <material>
              <coding>
                <system value="https://spor.ema.europa.eu/rmswi"/>
                <code value="200000003222"/>
                <display value="PolyVinyl Chloride"/>
              </coding>
            </material>
            <containedItem>
              <item>
                <reference>
                  <reference value="ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"/>
                </reference>
              </item>
            </containedItem>
          </packaging>
        </packaging>
      </PackagedProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/PackagedProductDefinition/ppd-6d93344139a7793e7b9bd0f5e32b6c91"/>
    <resource>
      <PackagedProductDefinition>
        <id value="ppd-6d93344139a7793e7b9bd0f5e32b6c91"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: PackagedProductDefinition</b><a name="ppd-6d93344139a7793e7b9bd0f5e32b6c91"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource PackagedProductDefinition &quot;ppd-6d93344139a7793e7b9bd0f5e32b6c91&quot; </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-PackagedProductDefinition-uv-epi.html">PackagedProductDefinition (ePI)</a></p></div><p><b>identifier</b>: id:Â EU/1/18/1289/001Â (use:Â OFFICIAL)</p><p><b>name</b>: Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion 30</p><p><b>type</b>: Chemical Medicinal Product <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000155527)</span></p><p><b>packageFor</b>: <a href="#MedicinalProductDefinition_mp2a9c4333cfd126f2e7b73ad3cafd6949">See above (MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949)</a></p><p><b>status</b>: Active <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-publication-status.html">PublicationStatus</a>#active)</span></p><p><b>statusDate</b>: 2012-02-07 13:28:17+0000</p><blockquote><p><b>packaging</b></p><p><b>type</b>: Box <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000073498)</span></p><p><b>quantity</b>: 1</p><p><b>material</b>: Cardboard <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#200000003529)</span></p><blockquote><p><b>packaging</b></p><p><b>identifier</b>: id:Â 654321</p><p><b>type</b>: Child-resistant closure <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000073504)</span></p><p><b>quantity</b>: 30</p><p><b>material</b>: PolyVinyl Chloride <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#200000003222)</span></p><blockquote><p><b>containedItem</b></p></blockquote></blockquote></blockquote></div>
        </text>
        <identifier>
          <use value="official"/>
          <system value="https://spor.ema.europa.eu/pmswi"/>
          <value value="EU/1/18/1289/001"/>
        </identifier>
        <name value="Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion 30"/>
        <type>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="100000155527"/>
            <display value="Chemical Medicinal Product"/>
          </coding>
        </type>
        <packageFor>
          <reference value="MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"/>
        </packageFor>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status"/>
            <code value="active"/>
            <display value="Active"/>
          </coding>
        </status>
        <statusDate value="2012-02-07T13:28:17Z"/>
        <packaging>
          <type>
            <coding>
              <system value="https://spor.ema.europa.eu/rmswi"/>
              <code value="100000073498"/>
              <display value="Box"/>
            </coding>
          </type>
          <quantity value="1"/>
          <material>
            <coding>
              <system value="https://spor.ema.europa.eu/rmswi"/>
              <code value="200000003529"/>
              <display value="Cardboard"/>
            </coding>
          </material>
          <packaging>
            <identifier>
              <system value="https://spor.ema.europa.eu/pmswi"/>
              <value value="654321"/>
            </identifier>
            <type>
              <coding>
                <system value="https://spor.ema.europa.eu/rmswi"/>
                <code value="100000073504"/>
                <display value="Child-resistant closure"/>
              </coding>
            </type>
            <quantity value="30"/>
            <material>
              <coding>
                <system value="https://spor.ema.europa.eu/rmswi"/>
                <code value="200000003222"/>
                <display value="PolyVinyl Chloride"/>
              </coding>
            </material>
            <containedItem>
              <item>
                <reference>
                  <reference value="ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"/>
                </reference>
              </item>
            </containedItem>
          </packaging>
        </packaging>
      </PackagedProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949"/>
    <resource>
      <MedicinalProductDefinition>
        <id value="mp2a9c4333cfd126f2e7b73ad3cafd6949"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: MedicinalProductDefinition</b><a name="mp2a9c4333cfd126f2e7b73ad3cafd6949"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource MedicinalProductDefinition &quot;mp2a9c4333cfd126f2e7b73ad3cafd6949&quot; </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-MedicinalProductDefinition-uv-epi.html">MedicinalProductDefinition (ePI)</a></p></div><p><b>identifier</b>: id:Â EU/1/18/1289/001, id:Â 0xF79CABF272B6A7EEF104DDDA44E827gy</p><p><b>type</b>: Medicinal Product <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-medicinal-product-type.html">Medicinal Product Type</a>#MedicinalProduct)</span></p><p><b>domain</b>: Human use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-medicinal-product-domain.html">Medicinal Product Domain</a>#Human)</span></p><p><b>status</b>: active <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-publication-status.html">PublicationStatus</a>#active)</span></p><p><b>legalStatusOfSupply</b>: Medicinal product subject to medical prescription <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#100000072084)</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion</p><p><b>type</b>: Full name <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (220000000000#220000000001)</span></p><blockquote><p><b>part</b></p><p><b>part</b>: Biktarvy</p><p><b>type</b>: Invented name part <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (220000000000#220000000002)</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: bictegravir/emtricitabine/tenofovir alafenamide</p><p><b>type</b>: Scientific name part <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (220000000000#220000000003)</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: 50 mg/200 mg/25 mg</p><p><b>type</b>: Strength part <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (220000000000#220000000004)</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: film-coated tablets</p><p><b>type</b>: Pharmaceutical dose form part <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (220000000000#220000000005)</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td>United Kingdom <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.3.0/CodeSystem-ISO3166Part1.html">ISO 3166-1 Codes for the representation of names of countries and their subdivisions â Part 1: Country code</a>#GBR)</span></td><td>United Kingdom <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.3.0/CodeSystem-ISO3166Part1.html">ISO 3166-1 Codes for the representation of names of countries and their subdivisions â Part 1: Country code</a>#GBR)</span></td><td>English <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.3.0/CodeSystem-v3-ietf3066.html">Tags for the Identification of Languages</a>#en)</span></td></tr></table></blockquote></div>
        </text>
        <identifier>
          <system value="https://spor.ema.europa.eu/pmswi"/>
          <value value="EU/1/18/1289/001"/>
        </identifier>
        <identifier>
          <system value="https://www.who-umc.org/phpid"/>
          <value value="0xF79CABF272B6A7EEF104DDDA44E827gy"/>
        </identifier>
        <type>
          <coding>
            <system value="http://hl7.org/fhir/medicinal-product-type"/>
            <code value="MedicinalProduct"/>
            <display value="Medicinal Product"/>
          </coding>
        </type>
        <domain>
          <coding>
            <system value="http://hl7.org/fhir/medicinal-product-domain"/>
            <code value="Human"/>
            <display value="Human use"/>
          </coding>
        </domain>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status"/>
            <code value="active"/>
            <display value="active"/>
          </coding>
        </status>
        <legalStatusOfSupply>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="100000072084"/>
            <display value="Medicinal product subject to medical prescription"/>
          </coding>
        </legalStatusOfSupply>
        <name>
          <productName value="Biktarvy 50 mg/200 mg/25 mg film-coated tabletsmg powder for concentrate for solution for infusion"/>
          <type>
            <coding>
              <system value="https://spor.ema.europa.eu/lists/220000000000"/>
              <code value="220000000001"/>
              <display value="Full name"/>
            </coding>
          </type>
          <part>
            <part value="Biktarvy"/>
            <type>
              <coding>
                <system value="https://spor.ema.europa.eu/lists/220000000000"/>
                <code value="220000000002"/>
                <display value="Invented name part"/>
              </coding>
            </type>
          </part>
          <part>
            <part value="bictegravir/emtricitabine/tenofovir alafenamide"/>
            <type>
              <coding>
                <system value="https://spor.ema.europa.eu/lists/220000000000"/>
                <code value="220000000003"/>
                <display value="Scientific name part"/>
              </coding>
            </type>
          </part>
          <part>
            <part value="50 mg/200 mg/25 mg"/>
            <type>
              <coding>
                <system value="https://spor.ema.europa.eu/lists/220000000000"/>
                <code value="220000000004"/>
                <display value="Strength part"/>
              </coding>
            </type>
          </part>
          <part>
            <part value="film-coated tablets"/>
            <type>
              <coding>
                <system value="https://spor.ema.europa.eu/lists/220000000000"/>
                <code value="220000000005"/>
                <display value="Pharmaceutical dose form part"/>
              </coding>
            </type>
          </part>
          <usage>
            <country>
              <coding>
                <system value="urn:iso:std:iso:3166"/>
                <code value="GBR"/>
                <display value="United Kingdom"/>
              </coding>
            </country>
            <jurisdiction>
              <coding>
                <system value="urn:iso:std:iso:3166"/>
                <code value="GBR"/>
                <display value="United Kingdom"/>
              </coding>
            </jurisdiction>
            <language>
              <coding>
                <system value="urn:ietf:bcp:47"/>
                <code value="en"/>
                <display value="English"/>
              </coding>
            </language>
          </usage>
        </name>
      </MedicinalProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="http://hl7.eu/fhir/ig/gravitate-health/ManufacturedItemDefinition/mid-94a96e39cfdcd8b378d12dd4063065f9"/>
    <resource>
      <ManufacturedItemDefinition>
        <id value="mid-94a96e39cfdcd8b378d12dd4063065f9"/>
        <meta>
          <profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ManufacturedItemDefinition-uv-epi"/>
        </meta>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: ManufacturedItemDefinition</b><a name="mid-94a96e39cfdcd8b378d12dd4063065f9"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource ManufacturedItemDefinition &quot;mid-94a96e39cfdcd8b378d12dd4063065f9&quot; </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info//StructureDefinition-ManufacturedItemDefinition-uv-epi.html">ManufacturedItemDefinition (ePI)</a></p></div><p><b>identifier</b>: id:Â EU/1/18/1289/001Â (use:Â OFFICIAL)</p><p><b>status</b>: active</p><p><b>manufacturedDoseForm</b>: Tablet <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#100000073664)</span></p><p><b>unitOfPresentation</b>: Tablet <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#200000002152)</span></p></div>
        </text>
        <identifier>
          <use value="official"/>
          <system value="https://spor.ema.europa.eu/pmswi"/>
          <value value="EU/1/18/1289/001"/>
        </identifier>
        <status value="active"/>
        <manufacturedDoseForm>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi/"/>
            <code value="100000073664"/>
            <display value="Tablet"/>
          </coding>
        </manufacturedDoseForm>
        <unitOfPresentation>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi"/>
            <code value="200000002152"/>
            <display value="Tablet"/>
          </coding>
        </unitOfPresentation>
      </ManufacturedItemDefinition>
    </resource>
  </entry>
</Bundle>